Trials / Completed
CompletedNCT05014438
A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis
A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients With Moderate to Severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986166 and of branebrutinib, each versus placebo, for the treatment of participants with moderate to severe atopic dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986166 | Specified dose on specified days |
| DRUG | Branebrutinib | Specified dose on specified days |
| OTHER | Placebo | Specified dose on specified days |
Timeline
- Start date
- 2021-08-17
- Primary completion
- 2022-08-22
- Completion
- 2022-08-22
- First posted
- 2021-08-20
- Last updated
- 2023-10-18
- Results posted
- 2023-10-18
Locations
42 sites across 7 countries: United States, Australia, Austria, Canada, Germany, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05014438. Inclusion in this directory is not an endorsement.